Unraveling the dynamics of the Omicron and Delta variants of the 2019 coronavirus in the presence of vaccination, mask usage, and antiviral treatment

[1]  Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. , 2023, The New England journal of medicine.

[2]  C. Ngonghala,et al.  The impact of age structure and vaccine prioritization on COVID-19 in West Africa , 2022, Infectious Disease Modelling.

[3]  S. Gharbia,et al.  Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant , 2022, The New England journal of medicine.

[4]  S. Bhatt,et al.  Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study , 2022, The Lancet.

[5]  J. Zahradník,et al.  Virological characteristics of SARS-CoV-2 BA.2 variant , 2022, bioRxiv.

[6]  Jiahui Chen,et al.  Omicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variant , 2022, ArXiv.

[7]  W. Hanage,et al.  Challenges in Inferring Intrinsic Severity of the SARS-CoV-2 Omicron Variant. , 2022, The New England journal of medicine.

[8]  James J. Davis,et al.  Signals of Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas , 2022, The American Journal of Pathology.

[9]  Cassandra Willyard.  What the Omicron wave is revealing about human immunity , 2022, Nature.

[10]  E. Klein,et al.  A Quick Displacement of the SARS-CoV-2 variant Delta with Omicron: Unprecedented Spike in COVID-19 Cases Associated with Fewer Admissions and Comparable Upper Respiratory Viral Loads , 2022, medRxiv.

[11]  K. Bruxvoort,et al.  Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants , 2022, Nature Medicine.

[12]  T. Burki.  Fourth dose of COVID-19 vaccines in Israel , 2022, The Lancet Respiratory Medicine.

[13]  C. del Rio,et al.  Winter of Omicron-The Evolving COVID-19 Pandemic. , 2021, JAMA.

[14]  J. Butterton,et al.  Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients , 2021, The New England journal of medicine.

[15]  A. M. Kilpatrick,et al.  Estimates of reduced vaccine effectiveness against hospitalization, infection, transmission and symptomatic disease of a new SARS-CoV-2 variant, Omicron (B.1.1.529), using neutralizing antibody titers , 2021, medRxiv.

[16]  Heidi Ledford,et al.  How bad is Omicron? What scientists know so far , 2021, Nature.

[17]  S. Karim,et al.  Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic , 2021, The Lancet.

[18]  D. Ramkrishna,et al.  Modeling of COVID-19 Transmission Dynamics on US Population: Inter-transfer Infection in Age Groups, Mutant Variants, and Vaccination Strategies , 2021, medRxiv.

[19]  David W. McDonald,et al.  Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[20]  S. W. Long,et al.  The Reemergence of Seasonal Respiratory Viruses in Houston, Texas, after Relaxing COVID-19 Restrictions , 2021, Microbiology spectrum.

[21]  S. Bhatt,et al.  SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion , 2021, Nature.

[22]  A. Salas,et al.  Superspreading in the emergence of COVID-19 variants , 2021, Trends in Genetics.

[23]  A. Gumel,et al.  Assessing the impact of widespread respirator use in curtailing COVID-19 transmission in the USA , 2021, Royal Society Open Science.

[24]  J. Tanne.  Covid-19: FDA approves Pfizer-BioNTech vaccine in record time , 2021, BMJ.

[25]  J. Tregoning,et al.  Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape , 2021, Nature reviews. Immunology.

[26]  R. Myers,et al.  Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant , 2021, The New England journal of medicine.

[27]  A. Galvani,et al.  Lives saved and hospitalizations averted by COVID-19 vaccination in New York City: a modeling study , 2021, The Lancet Regional Health - Americas.

[28]  C. Wiysonge,et al.  Understanding COVID-19 vaccine hesitancy , 2021, Nature Medicine.

[29]  M. Churpek,et al.  The impact of vaccination to control COVID-19 burden in the United States: A simulation modeling approach , 2021, PloS one.

[30]  A. Gumel,et al.  Will vaccine-derived protective immunity curtail COVID-19 variants in the US? , 2021, Infectious Disease Modelling.

[31]  H. Sacks.  The single-dose J&J vaccine had 67% efficacy against moderate to severe-critical COVID-19 at ≥14 d , 2021, Annals of Internal Medicine.

[32]  B. Ivorra,et al.  Modeling the impact of SARS-CoV-2 variants and vaccines on the spread of COVID-19 , 2021, Communications in Nonlinear Science and Numerical Simulation.

[33]  C. M. Saad-Roy,et al.  Vaccine nationalism and the dynamics and control of SARS-CoV-2 , 2021, Science.

[34]  J. Heffernan,et al.  Could a New COVID-19 Mutant Strain Undermine Vaccination Efforts? A Mathematical Modelling Approach for Estimating the Spread of B.1.1.7 Using Ontario, Canada, as a Case Study , 2021, Vaccines.

[35]  M. Koopmans,et al.  SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients , 2021, Science Immunology.

[36]  L. Abu-Raddad,et al.  Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants , 2021, The New England journal of medicine.

[37]  Ram Singh,et al.  Modeling, analysis and prediction of new variants of covid-19 and dengue co-infection on complex network , 2021, Chaos, Solitons & Fractals.

[38]  Ayelet Gneezy,et al.  COVID-19 and vaccine hesitancy: A longitudinal study , 2021, PloS one.

[39]  Greta M. Massetti,et al.  Mask Mandates, On-Premises Dining, and COVID-19. , 2021, JAMA.

[40]  Hannah Ritchie,et al.  A global database of COVID-19 vaccinations , 2021, Nature Human Behaviour.

[41]  A. Mitchell,et al.  Needlestick Injuries Among Healthcare Workers Administering COVID-19 Vaccinations in the United States , 2021, New solutions : a journal of environmental and occupational health policy : NS.

[42]  G. Troiano,et al.  Vaccine hesitancy in the era of COVID-19 , 2021, Public Health.

[43]  G. González-Parra,et al.  Impact of a new SARS-CoV-2 variant on the population: A mathematical modeling approach , 2021, medRxiv.

[44]  C. Nunes,et al.  Factors Associated with COVID-19 Vaccine Hesitancy , 2021, Vaccines.

[45]  H. Larson,et al.  Measuring the impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA , 2021, Nature Human Behaviour.

[46]  Malik Sallam.  COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates , 2021, Vaccines.

[47]  B. Singer,et al.  The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  Diana Duong.  What’s important to know about the new COVID-19 variants? , 2021, Canadian Medical Association Journal.

[49]  Elisabeth Mahase.  Covid-19: What new variants are emerging and how are they being investigated? , 2021, BMJ.

[50]  P. Hyland,et al.  Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom , 2021, Nature Communications.

[51]  N. Afonso,et al.  COVID-19 vaccine hesitancy among medical students , 2020, Journal of public health.

[52]  G. A. Ngwa,et al.  Toward Achieving a Vaccine-Derived Herd Immunity Threshold for COVID-19 in the U.S. , 2020, Frontiers in Public Health.

[53]  A. Gumel,et al.  A primer on using mathematics to understand COVID-19 dynamics: Modeling, analysis and simulations , 2020, Infectious Disease Modelling.

[54]  Elisabeth Mahase.  Covid-19: Moderna vaccine is nearly 95% effective, trial involving high risk and elderly people shows , 2020, BMJ.

[55]  A. Coustasse,et al.  COVID-19 and Vaccine Hesitancy , 2020, Journal of Ambulatory Care Management.

[56]  Shibo Jiang,et al.  Learning from the past: development of safe and effective COVID-19 vaccines , 2020, Nature Reviews Microbiology.

[57]  D. Beezhold,et al.  Efficacy of face masks, neck gaiters and face shields for reducing the expulsion of simulated cough-generated aerosols , 2020, Aerosol science and technology : the journal of the American Association for Aerosol Research.

[58]  B. Buonomo,et al.  Effects of information-induced behavioural changes during the COVID-19 lockdowns: the case of Italy , 2020, Royal Society Open Science.

[59]  G. Ayenigbara,et al.  COVID-19 (SARS-CoV-2) pandemic: fears, facts and preventive measures. , 2020, Germs.

[60]  A. Gumel,et al.  Could masks curtail the post-lockdown resurgence of COVID-19 in the US? , 2020, Mathematical Biosciences.

[61]  A. Dror,et al.  Vaccine hesitancy: the next challenge in the fight against COVID-19 , 2020, European Journal of Epidemiology.

[62]  B. Grenfell,et al.  Disease and healthcare burden of COVID-19 in the United States , 2020, Nature Medicine.

[63]  A. Gumel,et al.  Will an imperfect vaccine curtail the COVID-19 pandemic in the U.S.? , 2020, Infectious Disease Modelling.

[64]  Barney S. Graham,et al.  Rapid COVID-19 vaccine development , 2020, Science.

[65]  Chandini Raina MacIntyre,et al.  Mathematical assessment of the impact of non-pharmaceutical interventions on curtailing the 2019 novel Coronavirus , 2020, Mathematical Biosciences.

[66]  E. Kostelich,et al.  To mask or not to mask: Modeling the potential for face mask use by the general public to curtail the COVID-19 pandemic , 2020, Infectious Disease Modelling.

[67]  J. Snowdon,et al.  Emergence of Drift Variants That May Affect COVID-19 Vaccine Development and Antibody Treatment , 2020, Pathogens.

[68]  N. Lurie,et al.  Developing Covid-19 Vaccines at Pandemic Speed. , 2020, The New England journal of medicine.

[69]  Franco Blanchini,et al.  Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy , 2020, Nature Medicine.

[70]  B. Cowling,et al.  Respiratory virus shedding in exhaled breath and efficacy of face masks , 2020, Nature Medicine.

[71]  E. Dong,et al.  An interactive web-based dashboard to track COVID-19 in real time , 2020, The Lancet Infectious Diseases.

[72]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[73]  G. Chowell.  Fitting dynamic models to epidemic outbreaks with quantified uncertainty: A primer for parameter uncertainty, identifiability, and forecasts , 2017, Infectious Disease Modelling.

[74]  H. Larson,et al.  Vaccine hesitancy and healthcare providers. , 2016, Vaccine.

[75]  P. Beutels,et al.  Behavioural change models for infectious disease transmission: a systematic review (2010–2015) , 2016, Journal of The Royal Society Interface.

[76]  N. MacDonald.  Vaccine hesitancy: Definition, scope and determinants. , 2015, Vaccine.

[77]  H. Larson,et al.  Strategies for addressing vaccine hesitancy - A systematic review. , 2015, Vaccine.

[78]  Pejman Rohani,et al.  Avoidable errors in the modelling of outbreaks of emerging pathogens, with special reference to Ebola , 2014, Proceedings of the Royal Society B: Biological Sciences.

[79]  S. Omer,et al.  Epidemiology of vaccine hesitancy in the United States , 2013, Human vaccines & immunotherapeutics.

[80]  È. Dubé,et al.  Vaccine hesitancy , 2013, Human vaccines & immunotherapeutics.

[81]  Abba B. Gumel,et al.  Causes of backward bifurcations in some epidemiological models , 2012 .

[82]  B. Buonomo,et al.  Forces of Infection Allowing for Backward Bifurcation in an Epidemic Model with Vaccination and Treatment , 2012 .

[83]  Anthony S Fauci,et al.  The 1918 influenza pandemic: insights for the 21st century. , 2007, The Journal of infectious diseases.

[84]  J. Watmough,et al.  Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. , 2002, Mathematical biosciences.

[85]  M. Vickers,et al.  The efficacy of face masks. , 1983, Annals of the Royal College of Surgeons of England.

[86]  Rede de Informação e Conhecimento.  Coronavirus COVID-19 Global Cases by Johns Hopkins CSSE , 2020 .

[87]  Karyn L. Sutton,et al.  An Inverse Problem Statistical Methodology Summary , 2009 .

[88]  O. Diekmann,et al.  On the definition and the computation of the basic reproduction ratio R0 in models for infectious diseases in heterogeneous populations , 1990, Journal of mathematical biology.